Briggs S, Price MR, Tendler SJ (1993). “Fine specificity of antibody recognition of carcinoma-associated epithelial mucins: antibody binding to synthetic peptide epitopes”. European Journal of Cancer29A (2): 230–7. doi:10.1016/0959-8049(93)90181-E. PMID7678496.
Craig L, Sanschagrin PC, Rozek A, Lackie S, Kuhn LA, Scott JK (August 1998). “The role of structure in antibody cross-reactivity between peptides and folded proteins”. Journal of Molecular Biology281 (1): 183–201. doi:10.1006/jmbi.1998.1907. PMID9680484.
Steers NJ, Currier JR, Jobe O, Tovanabutra S, Ratto-Kim S, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M (June 2014). “Designing the epitope flanking regions for optimal generation of CTL epitopes”. Vaccine32 (28): 3509–16. doi:10.1016/j.vaccine.2014.04.039. PMID24795226.
De Groot AS, Martin W (May 2009). “Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics”. Clinical Immunology131 (2): 189–201. doi:10.1016/j.clim.2009.01.009. PMID19269256.
Bergmann CC, Yao Q, Ho CK, Buckwold SL (October 1996). “Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes”. Journal of Immunology157 (8): 3242–9. PMID8871618.
Briggs S, Price MR, Tendler SJ (1993). “Fine specificity of antibody recognition of carcinoma-associated epithelial mucins: antibody binding to synthetic peptide epitopes”. European Journal of Cancer29A (2): 230–7. doi:10.1016/0959-8049(93)90181-E. PMID7678496.
Craig L, Sanschagrin PC, Rozek A, Lackie S, Kuhn LA, Scott JK (August 1998). “The role of structure in antibody cross-reactivity between peptides and folded proteins”. Journal of Molecular Biology281 (1): 183–201. doi:10.1006/jmbi.1998.1907. PMID9680484.
Steers NJ, Currier JR, Jobe O, Tovanabutra S, Ratto-Kim S, Marovich MA, Kim JH, Michael NL, Alving CR, Rao M (June 2014). “Designing the epitope flanking regions for optimal generation of CTL epitopes”. Vaccine32 (28): 3509–16. doi:10.1016/j.vaccine.2014.04.039. PMID24795226.
De Groot AS, Martin W (May 2009). “Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics”. Clinical Immunology131 (2): 189–201. doi:10.1016/j.clim.2009.01.009. PMID19269256.